- Home
- GNTA vs IMRX Comparison
GNTA vs IMRX Comparison
Compare GNTA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- IMRX
- Stock Information
- Founded
- GNTA 2014
- IMRX 2008
- Country
- GNTA Italy
- IMRX United States
- Employees
- GNTA N/A
- IMRX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- IMRX Health Care
- Exchange
- GNTA Nasdaq
- IMRX Nasdaq
- Market Cap
- GNTA 71.9M
- IMRX 62.7M
- IPO Year
- GNTA 2021
- IMRX 2021
- Fundamental
- Price
- GNTA $3.96
- IMRX $1.76
- Analyst Decision
- GNTA Strong Buy
- IMRX Buy
- Analyst Count
- GNTA 1
- IMRX 7
- Target Price
- GNTA $25.00
- IMRX $12.20
- AVG Volume (30 Days)
- GNTA 5.4K
- IMRX 319.9K
- Earning Date
- GNTA 01-01-0001
- IMRX 03-04-2025
- Dividend Yield
- GNTA N/A
- IMRX N/A
- EPS Growth
- GNTA N/A
- IMRX N/A
- EPS
- GNTA N/A
- IMRX N/A
- Revenue
- GNTA N/A
- IMRX N/A
- Revenue This Year
- GNTA N/A
- IMRX N/A
- Revenue Next Year
- GNTA N/A
- IMRX N/A
- P/E Ratio
- GNTA N/A
- IMRX N/A
- Revenue Growth
- GNTA N/A
- IMRX N/A
- 52 Week Low
- GNTA $2.20
- IMRX $1.00
- 52 Week High
- GNTA $7.28
- IMRX $7.68
- Technical
- Relative Strength Index (RSI)
- GNTA 47.29
- IMRX 40.02
- Support Level
- GNTA $3.76
- IMRX $1.70
- Resistance Level
- GNTA $4.13
- IMRX $1.92
- Average True Range (ATR)
- GNTA 0.29
- IMRX 0.09
- MACD
- GNTA 0.04
- IMRX -0.01
- Stochastic Oscillator
- GNTA 34.29
- IMRX 15.00
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.